Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 1.76 | 1.36 |
NAV | ₹211.77 | ₹200.81 |
Fund Started | 12 Feb 2001 | 07 May 2007 |
Fund Size | ₹8262.25 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 0.50% if redeemed within 3 months. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -8.26% | 6.10% |
3 Year | 16.17% | 25.05% |
5 Year | 26.19% | 28.68% |
1 Year
3 Year
5 Year
Equity | 98.38% | 93.60% |
Cash | -0.30% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Nifty MidCap Select Index | 8.85% |
Aurobindo Pharma Ltd. | 7.83% |
Tata Communications Ltd. | 7.74% |
Premier Energies Ltd. | 6.85% |
Reliance Industries Ltd. | 6.82% |
IRB Infrastructure Developers Ltd. | 6.37% |
Lloyds Metals & Energy Ltd. | 5.44% |
Lupin Ltd. | 4.95% |
GMR Airports Ltd. | 4.79% |
Linde India Ltd. | 3.62% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Ankit A Pande | Chirag Setalvad |
Start Date | 07 Jul 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme aims at providing long term capital appreciation and generating income with a diversified portfolio of Mid Cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 12 Feb 2001 | 07 May 2007 |
Description
Launch Date